Beyond Air (NASDAQ:XAIR) Announces Quarterly Earnings Results, Misses Estimates By $0.31 EPS

Beyond Air (NASDAQ:XAIR) posted its quarterly earnings results on Friday. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.31), Zacks reports. Beyond Air had a negative return on equity of 261.08% and a negative net margin of 632.51%.The company had revenue of $2.19 million during the quarter, compared to analyst estimates of $2.15 million.

Here are the key takeaways from Beyond Air’s conference call:

• Revenue grew 105% year‑over‑year to $2.2M, with an installed base of more than 45 hospitals, customer retention above 90%, and over half of customers on multi‑year agreements, indicating early commercial traction.
• Commercial momentum includes national GPO agreements with Premier and Vizient, the first sale into a VA Medical Center, expansion of distribution to 40 countries, and repeat international accessory orders, supporting broader adoption.
• Management expects FDA clearance for the Gen 2 LungFit PH system by the end of calendar 2026 and says Gen 2’s smaller size, transport compatibility, simplified operation, and extended service intervals should expand the addressable market.
• Timing risk remains for Gen 2 because launch is contingent on a contract manufacturer inspection and continued engagement with the FDA, which could delay approval or commercialization.
• Operating expenses fell ~36% YoY to about $6.9M, net loss narrowed to $7.3M, cash and equivalents were $17.8M at quarter end, and subsequent financings give management confidence in a runway into calendar 2027, albeit conditional on meeting revenue and cost targets.

Beyond Air Price Performance

Shares of XAIR traded up $0.06 on Friday, hitting $1.08. The company’s stock had a trading volume of 448,222 shares, compared to its average volume of 15,107,503. The company has a market capitalization of $8.62 million, a PE ratio of -0.14 and a beta of 0.39. Beyond Air has a fifty-two week low of $0.67 and a fifty-two week high of $8.01. The company has a 50 day moving average price of $1.14 and a 200 day moving average price of $1.83. The company has a debt-to-equity ratio of 0.77, a current ratio of 4.24 and a quick ratio of 3.73.

Analyst Ratings Changes

XAIR has been the subject of several research reports. D. Boral Capital reiterated a “buy” rating and issued a $11.00 target price on shares of Beyond Air in a research note on Wednesday, January 21st. Rodman & Renshaw started coverage on Beyond Air in a report on Tuesday, January 20th. They issued a “buy” rating for the company. Finally, Weiss Ratings reissued a “sell (e)” rating on shares of Beyond Air in a report on Monday, December 22nd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Beyond Air presently has an average rating of “Hold” and an average price target of $11.00.

Hedge Funds Weigh In On Beyond Air

A number of institutional investors and hedge funds have recently bought and sold shares of XAIR. Alyeska Investment Group L.P. bought a new stake in shares of Beyond Air during the third quarter worth $1,753,000. Osaic Holdings Inc. lifted its position in Beyond Air by 26.4% during the 2nd quarter. Osaic Holdings Inc. now owns 162,560 shares of the company’s stock worth $29,000 after buying an additional 34,000 shares in the last quarter. Geode Capital Management LLC grew its holdings in Beyond Air by 57.5% during the 4th quarter. Geode Capital Management LLC now owns 67,678 shares of the company’s stock worth $49,000 after acquiring an additional 24,695 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Beyond Air in the third quarter worth about $48,000. Institutional investors and hedge funds own 31.50% of the company’s stock.

About Beyond Air

Beyond Air, Inc is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.

The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity.